REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [41] Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Meyerhardt, JA
    Zhu, AX
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Earle, CC
    Vincitore, M
    Michelini, A
    Sheehan, S
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1892 - 1897
  • [42] Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer
    Pavia, OA
    Cangiano, J
    Crisostomo, R
    Caceres, W
    Barranco, E
    Wright, M
    Antonia, T
    Antonia, S
    Sullivan, D
    Garrett, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 307S - 307S
  • [43] Randomized phase ll study of oxaliplatin reintroduction and biweekly XELOX in previously treated patients with metastatic colorectal cancer (mCRC): ORION study
    Keiichiro, I.
    Ishibashi, K.
    Matsuda, C.
    Tamagawa, H.
    Munemoto, Y.
    Tanaka, C.
    Fukunaga, M.
    Tokunaga, Y.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [44] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [45] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [46] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [47] A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    Ryan, DP
    Clark, JW
    Kulke, MH
    Fuchs, CS
    Earle, CC
    Enzinger, PC
    Stuart, K
    Catarius, KJ
    Winkelmann, J
    Mayer, RJ
    CANCER INVESTIGATION, 2003, 21 (04) : 505 - 511
  • [48] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [49] Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
    Bécouarn, Y
    Gamelin, E
    Coudert, B
    Négrier, S
    Pierga, JY
    Raoul, JL
    Provençal, J
    Rixe, O
    Krisch, C
    Germa, C
    Bekradda, M
    Mignard, D
    Mousseau, M
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4195 - 4201
  • [50] A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Jensen, Helle Anita
    Vestermark, Lene Weber
    Farr, Katherina Podlekareva
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345